KESTRA MEDICAL TECHNOLOGIES, LTD.(KMTS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,565 of 2,960 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
KMTS Stock Analysis & AI Quality Score
Data updated 2026-09-12AI stock analysis and institutional research for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KMTS at 28.1/100 on a 32-signal composite quality model, placing it at rank #2,565 of 2,960 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q1 2026), KESTRA MEDICAL TECHNOLOGIES, LTD. reports quarterly revenue of $28.6M, net income of $-38.8M, free cash flow of $-28.4M. Top institutional holders of KMTS by reported 13-F value include BAIN CAPITAL INVESTORS, FMR, PRICE T ROWE ASSOCIATES, based on the most recent SEC filings. KMTS trades on the Nasdaq exchange and files with the SEC under CIK 1877184. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KMTS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KESTRA MEDICAL TECHNOLOGIES, LTD. directly from SEC EDGAR. KESTRA MEDICAL TECHNOLOGIES, LTD.'s 13F Pro composite quality score has ranged between 28 and 33 since 2025, currently 28.1 — a stable long-term trajectory across 50 quarterly and live scoring snapshots.
Revenue
Q1 2026
$28.6M
Net Income
Q1 2026
$-38.8M
Free Cash Flow
Q1 2026
$-28.4M
ROIC
Q1 2026
-52.1%
D/E Ratio
Q1 2026
0.16
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+59.0% YoYNet Income
-15.6% YoYOperating Income
-26.7% YoYEPS (Diluted)
+52.6% YoYTotal Assets
+21.2% YoYTotal Debt
+3.8% YoYOp. Cash Flow
-5.3% YoYFree Cash Flow
-16.0% YoY| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Revenue | $95.1M +59.0% | $59.8M +115.1% | $27.8M | — |
| Net Income | $-131.6M -15.6% | $-113.8M -20.9% | $-94.1M | — |
| Operating Income | $-134.7M -26.7% | $-106.4M -25.1% | $-85.1M | — |
| EPS (Diluted) | $-2.43 +52.6% | $-5.13 -1.2% | $-5.07 | — |
| Total Assets | $358.5M +21.2% | $295.7M +543.6% | $45.9M | — |
| Total Debt | $42.6M +3.8% | $41.1M -3.4% | $42.5M | — |
| Operating Cash Flow | $-81.7M -5.3% | $-77.6M -7.4% | $-72.2M | — |
| Free Cash Flow | $-116.6M -16.0% | $-100.5M -19.0% | $-84.5M | — |
Get alerted when KMTS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for KESTRA MEDICAL TECHNOLOGIES, LTD. including:
Top Institutional Holders of KMTS
BAIN CAPITAL INVESTORS LLC
$640.4M25,172,338 shFMR LLC
$140.5M5,523,647 shPRICE T ROWE ASSOCIATES INC /MD/
$126.4M4,968,900 shAndera Partners
$69.4M2,728,679 shYu Fan
$58.1M2,282,519 shBROWN ADVISORY INC
$48.6M1,909,056 shBlackRock, Inc.
$47.5M1,865,496 shEVENTIDE ASSET MANAGEMENT, LLC
$36.8M1,446,742 shVANGUARD CAPITAL MANAGEMENT LLC
$29.9M1,175,525 shALLIANCEBERNSTEIN L.P.
$29.5M1,477,992 sh
| Fund | Value | Shares |
|---|---|---|
| BAIN CAPITAL INVESTORS LLC | $640.4M | 25,172,338 |
| FMR LLC | $140.5M | 5,523,647 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $126.4M | 4,968,900 |
| Andera Partners | $69.4M | 2,728,679 |
| Yu Fan | $58.1M | 2,282,519 |
| BROWN ADVISORY INC | $48.6M | 1,909,056 |
| BlackRock, Inc. | $47.5M | 1,865,496 |
| EVENTIDE ASSET MANAGEMENT, LLC | $36.8M | 1,446,742 |
| VANGUARD CAPITAL MANAGEMENT LLC | $29.9M | 1,175,525 |
| ALLIANCEBERNSTEIN L.P. | $29.5M | 1,477,992 |
Companies Similar to KMTS
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Beta Bionics, Inc.
Viridian Therapeutics, Inc.\DE
Kymera Therapeutics, Inc.
CYTOKINETICS INC
Crinetics Pharmaceuticals, Inc.
Tango Therapeutics, Inc.
Invivyd, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put KMTS on your watchlist
Track score changes the day KESTRA MEDICAL TECHNOLOGIES, LTD. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KMTS a good stock to buy?
13F Pro's AI-powered analysis of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KMTS are available on the KMTS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. KMTS is classified as a small company.
Which hedge funds own KMTS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KMTS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of KESTRA MEDICAL TECHNOLOGIES, LTD.'s investment landscape.